Ge Healthcare Technologies Stock Earnings Reports

GE HealthCare delivered a solid top-line quarter (Q1 2026 revenue $5.1B; 2.9% organic growth) with strength in Pharmaceutical Diagnostics (PDx), Advanced Visualization Solutions, Imaging (notably CT and X‑ray) and services. Orders, book‑to‑bill (1.07x) and backlog ($21.8B, record) were healthy, with double‑digit reported growth in EMEA and Rest of World. Key commercial and product milestones: U.S. and Japan clearances for the Photonova Spectra photon‑counting CT, multiple FDA clearances for next‑gen MR (including new 3T / reduced‑helium platforms and AI workflow), continued Flyrcado radiopharmaceutical ramp (approx. 390 doses/week mid‑April; trajectory supporting $500M+ target by 2028), and dosing start for a manganese‑based gadolinium‑free MRI contrast candidate (Phase II/III; Fast Track). Strategic actions: closed Intelerad acquisition to expand cloud/enterprise imaging, reorganized into three segments (Advanced Imaging Solutions (AIS), PDx, Patient Care Solutions (PCS)), and created a new global markets region. Financials disappointed on profit: adjusted EBIT margin 13.5% (down ~150 bps y/y) and adjusted EPS $0.99, impacted by a PDx supplier recall and meaningful commodity inflation. Management quantified a gross inflation headwind of about $250M (~$0.43/share) primarily from memory chips (~$100M) and oil/freight (~$100M), plus other commodities (~$50M). They expect to offset more than half of the inflation with price and cost actions but reduced 2026 guidance: maintaining organic sales growth of 3–4% but lowering adjusted EPS to $4.80–$5.00 (mid‑to‑high single‑digit EPS growth) and free cash flow to ~ $1.6B. Tariff impacts are expected to be lower than 2025 but still present; Intelerad is modestly dilutive in 2026 and accretive thereafter. Management expects revenue acceleration and margin improvement in H2 2026 as mitigation and new product adoption take effect, with more meaningful revenue contribution from major NPIs beginning in H1 2027.